Emerging Markets Earnings: Lantus Sighted As Lodestar For Sanofi Board
This article was originally published in PharmAsia News
Former Sanofi chief executive Chris Viehbacher gives a swan song in the third quarter earnings call that highlighted progress in emerging markets, but not enough on Lantus to save his job as Serge Weinberg made clear the next day.
You may also be interested in...
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.